Senseonics (NYSE:SENS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of Senseonics (NYSE:SENS) in a report published on Thursday. The brokerage issued a sell rating on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $2.00 price target on shares of Senseonics in a research note on Wednesday, August 14th.

Senseonics Stock Performance

Shares of NYSE SENS opened at $0.34 on Thursday. The company has a current ratio of 3.11, a quick ratio of 2.89 and a debt-to-equity ratio of 59.17. Senseonics has a one year low of $0.32 and a one year high of $0.75. The business has a 50-day moving average price of $0.36 and a two-hundred day moving average price of $0.40. The firm has a market capitalization of $181.93 million, a PE ratio of -2.61 and a beta of 0.79.

Senseonics (NYSE:SENS) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). The business had revenue of $4.87 million during the quarter, compared to analysts’ expectations of $4.86 million. Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. As a group, analysts predict that Senseonics will post -0.13 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Senseonics

Several large investors have recently made changes to their positions in SENS. State Board of Administration of Florida Retirement System acquired a new stake in Senseonics in the first quarter valued at approximately $91,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Senseonics by 30.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after purchasing an additional 211,128 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after purchasing an additional 51,000 shares in the last quarter. Vanguard Group Inc. increased its position in Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Senseonics during the first quarter valued at about $162,000. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.